INSYS Therapeutics, Inc.

The biggest approval headlines of the past week came from well-established molecules, as the US FDA cleared a major new indication outside of diabetes for AstraZeneca PLC ’s Farxiga and a higher-dose

Thousands of documents disclosed in litigation against opioid makers and distributors have been collected in an archive that is available to the public at no cost. The digital repository is intended t

Biopharma executives and outside counsel honed in on several issues that could impact the way companies promote their medical products at the Food and Drug Law Institute’s advertising and promotion co

The US government is encouraging biopharma companies to do away with in-person speaker programs, citing the risk that payments made to speakers for informing healthcare professionals about their produ